Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
VESPER-4
Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)
4 other identifiers
interventional
3,578
10 countries
170
Brief Summary
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Dec 2025
170 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 19, 2025
CompletedFirst Submitted
Initial submission to the registry
December 29, 2025
CompletedFirst Posted
Study publicly available on registry
December 31, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 21, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 25, 2028
July 24, 2026
July 1, 2026
1.8 years
December 29, 2025
July 23, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Percent change from baseline in body weight
Baseline (Day 0) to Week 64
Secondary Outcomes (38)
Percentage of Participants who achieve ≥5% of reduction from baseline body weight
Baseline (Day 0) to Week 64
Percentage of Participants who achieve ≥10% of reduction from baseline body weight
Baseline (Day 0) to Week 64
Percentage of Participants who achieve ≥15% of reduction from baseline body weight
Baseline (Day 0) to Week 64
Percentage of Participants who achieve ≥20% of reduction from baseline body weight
Baseline (Day 0) to Week 64
Change from baseline in Fasting triglycerides
Baseline (Day 0) to Week 64
- +33 more secondary outcomes
Study Arms (4)
MET097 Dose 1
EXPERIMENTALParticipants will receive MET097 administered subcutaneously
MET097 Dose 2
EXPERIMENTALParticipants will receive MET097 administered subcutaneously
MET097 Dose 3
EXPERIMENTALParticipants will receive MET097 administered subcutaneously
Placebo
PLACEBO COMPARATOROnce-weekly placebo administered via subcutaneous injection
Interventions
Eligibility Criteria
You may qualify if:
- BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to \<30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
You may not qualify if:
- Have any form of diabetes
- Have a self-reported body weight change \> 5 kg (11 pounds) within 3 months prior to Screening
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (170)
Headlands Research
Scottsdale, Arizona, 85260, United States
Alliance Research Institute
Canoga Park, California, 91304, United States
Collaborative Neuroscience Research, LLC
Garden Grove, California, 92845, United States
Clinical Innovations, Inc dba CITrials
Riverside, California, 92506, United States
Peninsula Headlands LLC
Rolling Hills, California, 90274, United States
CenExcel Rocky Mountain Clinical Research, LLC
Englewood, Colorado, 80113, United States
Research Centers of America
Hollywood, Florida, 33024, United States
Future Medical Research (Civia Health)
Longwood, Florida, 32750, United States
Advanced Clinical Research
Miami, Florida, 33156, United States
Oviedo Medical Research
Oviedo, Florida, 32765, United States
CenExel FCR - ForCare Clinical Research
Tampa, Florida, 33613, United States
DelRicht Research
Atlanta, Georgia, 30329, United States
CenExel iResearch, LLC
Savannah, Georgia, 31405, United States
CenExel CBH Health
Gaithersburg, Maryland, 20877, United States
Clinical Research Professionals
Chesterfield, Missouri, 63005, United States
Upgrade Performance Institute
Elkhorn, Nebraska, 68022, United States
Quality Clinical Research Inc
Omaha, Nebraska, 68114, United States
Primary clinical Research
Papillion, Nebraska, 68046, United States
Hassman Research Institute
Marlton, New Jersey, 08053, United States
Forum Health Cary
Cary, North Carolina, 27511, United States
Eximia EquiHealth Research
Durham, North Carolina, 27704, United States
Sahana Optometry PLLC dba Family Eye Wellness
Holly Springs, North Carolina, 27540, United States
TMA Headlands LLC - Wilmington
Wilmington, North Carolina, 28403, United States
TMA Headlands LLC
Wilmington, North Carolina, 28403, United States
Summit Headlands LLC
Portland, Oregon, 97210, United States
Tribe Clinical Research LLC.- Greenville
Greenville, South Carolina, 29607, United States
Palmetto Internal Medicine
Mauldin, South Carolina, 29662, United States
Tribe Clinical Research LLC. - Spartanburg
Spartanburg, South Carolina, 29301, United States
Civia Health Goodlettsville
Goodlettsville, Tennessee, 37072, United States
Civia Health Nashville
La Vergne, Tennessee, 37086, United States
Civia Health Memphis
Memphis, Tennessee, 38117, United States
Forum Austin (Civia Health)
Austin, Texas, 78758, United States
Cedar Health Research
Dallas, Texas, 75251, United States
GLRI El Paso Research
El Paso, Texas, 79936, United States
Dallas Clinical Research Center (Pillar Clinical Research)
Richardson, Texas, 75080, United States
Pantheon Clinical Research
Bountiful, Utah, 84010, United States
MHAT Botevgrad
Botevgrad, 2140, Bulgaria
Medical Center 4Life EOOD
Burgas, 8018, Bulgaria
Multiprofile Hospital for Active Treatment Dobrich AD (MHAT Dobrich AD)
Dobrich, 9300, Bulgaria
Medical Center New Polyclinic Gabrovo Ltd.
Gabrovo, 5300, Bulgaria
Medical Center Zdrave 1
Kozloduy, 3320, Bulgaria
Medical Center Futuremeds EOOD
Plovdiv, 4000, Bulgaria
MHAT Sveta Karidad EAD
Plovdiv, 4004, Bulgaria
Diagnostic Consultative Center Aleksandrovska
Sofia, 1431, Bulgaria
Medical Center Hera EOOD
Sofia, 1510, Bulgaria
Prevencia - 2000 - Medical Center for Prehospital Medical Care OOD
Stara Zagora, 6000, Bulgaria
Medical Center - Clinic Nova EOOD
Varna, 9020, Bulgaria
Medical Centre Pratia Clinic EOOD
Varna, 9020, Bulgaria
MC Nevromedics Ltd.
Veliko Tarnovo, 5005, Bulgaria
Medical Center Berbatov
Yambol, 8600, Bulgaria
Centricity Research Etobicoke Endocrinology
Etobicoke, Ontario, M9R 4E1, Canada
The Wharton Medical Clinic Clinical Trials Inc
Hamilton, Ontario, L8L 5G8, Canada
LMC Diabetes & Endocrinology - Bayview (Centricity Research Toronto LMC Multispecialty)
Toronto, Ontario, M4G 3E8, Canada
Centricity Research Mirabel Multispecialty (Centricity Research)
Mirabel, Quebec, J7J 2K8, Canada
Pratia Brno,s.r.o
Brno, 60200, Czechia
Nemocnice Jihlava
Jihlava, 58601, Czechia
Edumed s.r.o.
Náchod, 54701, Czechia
Agentura science pro s.r.o.
Olomouc, 77900, Czechia
CCR Ostrava
Ostrava, 702 00, Czechia
Pratia Pardubice
Pardubice, 53002, Czechia
Fakultní nemocnice Královské Vinohrady
Prague, 100 34, Czechia
Synexus/Trialmed Prague
Prague, 120 00, Czechia
ResTrial s.r.o.
Prague, 18100, Czechia
CDG Studienambulanz Hartard
Munich, Bavaria, 80809, Germany
Studienzentrum FMZ Radowsky
Leipzig, Saxony, 4179, Germany
Zentrum für klinische Studien Bad Homburg
Bad Homburg, 61348, Germany
Klinische Forschung Berlin-Mitte GmbH
Berlin, 10117, Germany
FutureMeds Berlin
Berlin, 10629, Germany
Velocity Clinical Research Germany
Berlin, 10787, Germany
Diabetespraxis Dr. Braun
Berlin, 13187, Germany
Zentrum für klinische Forschung
Cologne, 51069, Germany
Klinische Forschung Dresden GmbH / Pratia
Dresden, 01069, Germany
Medizentrum Essen Borbeck
Essen, 45355, Germany
Praxis am Markt - Dr. Bernd Becker
Essen, 45355, Germany
Klinische Forschung Hamburg GmbH / Pratia
Hamburg, 20253, Germany
Diabeteszentrum Hamburg-West
Hamburg, 22607, Germany
Praxis Reinfeld Mitte
Holstein, 23858, Germany
Klinische Forschung Karlsruhe GmbH
Karlsruhe, 76137, Germany
AmBeNet GmbH
Leipzig, 4107, Germany
Gemeinschaftspraxis Dres. H.Kittner und K.Hartig
Naunhof, 04683, Germany
FutureMeds Frankfurt/Offenbach
Offenbach, 63065, Germany
Zentrum für klinische Forschung Allgäu-Oberschwaben
Wangen, 88239, Germany
Medislim GmbH
Weinheim, 69469, Germany
Zdrowie Osteo Medic sc L i A Racewicz, A i J Supronik
Bialystok, 15-351, Poland
NZOZ Centrum Medyczne KERmed
Bydgoszcz, 85-231, Poland
Centrum medyczne Pratia Bydgoszcz
Bydgoszcz, 85-796, Poland
Pratia Chojnice
Chojnice, 89-600, Poland
Synexus Polska Sp. z o.o., Oddzial w Czestochowie
Częstochowa, 42-202, Poland
Synexus Polska Sp z o.o.
Gdansk, 80-382, Poland
Centrum Badan Klinicznych PI-House Sp. z o.o.
Gdansk, 80-546, Poland
Centrum Medyczne Pratia Gdynia
Gdynia, 81-338, Poland
FutureMeds Gdynia
Gdynia, 81-384, Poland
Synexus Polska Sp. z o.o. Oddzial w Gdyni
Gdynia, 81-537, Poland
Synexus Polska Sp. Z O.O. Oddzial W Katowicach
Katowice, 40-040, Poland
Centrum Medyczne Pratia Katowice
Katowice, 40-081, Poland
FutureMeds Krakow
Krakow, 31-501, Poland
Synexus Polska Sp. z o.o., Oddzial w Lodzi
Lodz, 90-127, Poland
Centrum Terapii Współczesnej J.M. Jasnorzewska Spółka Komandytowo-Akcyjna
Lodz, 90-338, Poland
FutureMeds Lodz
Lodz, 91-393, Poland
Ekamed Sp. z o. o.
Lublin, 20-718, Poland
FutureMeds Olsztyn
Olsztyn, 10-165, Poland
Medicome Sp. z o.o. Oświęcimskie Centrum Badań Klinicznych
Oświęcim, 32-600, Poland
IRMED
Piotrkow Trybunalski, 97-300, Poland
Trialmed CRS
Piotrkow Trybunalski, 97-300, Poland
Synexus Polska Sp. z o.o., Oddział w Poznaniu
Poznan, 60-702, Poland
Praktyka Lekarska Ewa Krzyzagorska
Poznan, 61-655, Poland
ETG Siedlce
Siedlce, 08-110, Poland
Metabolica Sp. z o.o., NZOZ METABOLICA Ośrodek Badań Klinicznych
Tarnów, 33-100, Poland
FutureMeds Warszawa Centrum
Warsaw, 00-215, Poland
Instytut Diabetologii.sp.z.o.o.
Warsaw, 02-117, Poland
Synexus Polska Sp. z o.o., Oddzial w Warszawie
Warsaw, 02-672, Poland
Etg Warszawa
Warsaw, 02-677, Poland
FutureMeds Warszawa Targowek
Warsaw, 03-291, Poland
Synexus Polska Sp. z o.o., Oddział we Wrocławiu
Wroclaw, 50-381, Poland
FutureMeds Wroclaw
Wroclaw, 53-673, Poland
Santa Familia PTG Lodz
Lodz, Łódź Voivodeship, 90-302, Poland
Minimed S.R.L.
Bacau, 600237, Romania
Futuremeds S.R.L., Brasov
Brasov, 500388, Romania
Hightech Medical Services S.R.L (Centrul pentru Studiul Metabolismului)
Bucharest, 011053, Romania
Institutul National de Endocrinologie "C.I. Parhon"
Bucharest, 011863, Romania
Institutul Clinic Fundeni
Bucharest, 022328, Romania
Fundatia Dr Victor Babes
Bucharest, 30303, Romania
Futuremeds S.R.L., Craiova
Criaova, 200115, Romania
Futuremeds S.R.L., Galati
Galati, 800183, Romania
Centru Medical "GRANDMED"
Oradea, 410032, Romania
Sc Gensan Srl/Policlinica Astra
Sibiu, 550371, Romania
Centrul Medical Mediab - Mediab Srl
Târgu Mureş, 540142, Romania
DIABEDA s.r.o.
Bratislava, 831 06, Slovakia
Medispektrum s.r.o.
Bratislava, 85101, Slovakia
Poliklinika Váš Lekár
Bratislava - Ružinov, 91109, Slovakia
Cardio D&R Košice
Košice, 040 22, Slovakia
Medical group Kosice s.r.o.
Košice, 04001, Slovakia
Tatratrial s.r.o.
Rožňava, 048 01, Slovakia
MEDI-DIA s.r.o
Sabinov, 083 01, Slovakia
JAL s.r.o
Trnava, 91701, Slovakia
Medivasa s.r.o
Žilina, 010 01, Slovakia
Hospital Universitario Virgen de la Victoria
Málaga, Málaga, 29010, Spain
Hospital Vithas Sevilla
Castilleja de la Cuesta, 41950, Spain
Futuremeds Spain Cadiz
Chiclana de la Frontera, 11139, Spain
Futuremeds Spain Madrid
Madrid, 28003, Spain
Hospital Virgen del Camino
Sanlúcar de Barrameda, 11540, Spain
Nuevas Tecnologías en Diabetes y Endocrinología S.L.
Seville, 41003, Spain
Futuremeds Spain Sevilla
Seville, 41012, Spain
Ecg Médica S.L.
Valencia, 46015, Spain
Ashfields Primary Care Center
Sandbach, Cheshire, CW11 1EQ, United Kingdom
Civia Health Sunderland
Hendon, CITY of Sunderland, SR1 1PB, United Kingdom
FutureMeds Glasgow McCafferty House
Glasgow, Scotland, G20 7BE, United Kingdom
Synexus Glasgow Clinical Research Centre
Bellshill, ML4 3NJ, United Kingdom
Synexus Midlands Clinical Research Centre
Birmingham, B15 2SQ, United Kingdom
FutureMeds Birmingham
Birmingham, B21 9RY, United Kingdom
Civia Health_Boots Birmingham
Birmingham, B4 7TA, United Kingdom
Southmead Hospital
Bristol, BS10 5NB, United Kingdom
FutureMeds Liverpool
Bromborough, CH62 6EE, United Kingdom
Panthera Biopartners Limited - Enfield
Enfield, EN3 4GS, United Kingdom
Panthera Biopartners Limited - Glasgow
Glasgow, G51 4TY, United Kingdom
Bodyline Medical Clinic, Crosby Civia Health
Liverpool, L22 4QQ, United Kingdom
FutureMeds London
London, NW10 2PB, United Kingdom
Synexus Manchester Clinical Research Centre
Manchester, M15 6SE, United Kingdom
Kiltearn Medical Centre
Nantwich, CW5 5NX, United Kingdom
FutureMeds Newcastle upon Tyne
Newcastle upon Tyne, NE6 1SG, United Kingdom
Civia Health_Boots Nottingham
Nottingham, NG1 3QS,, United Kingdom
Bodyline Medical Clinic Warrington Civia Health
Paddington, WA1 3TZ, United Kingdom
Panthera Biopartners Limited - Preston
Preston, PR2 9QB, United Kingdom
Panthera Biopartners Limited - Rochdale
Rochdale, OL11 4AU, United Kingdom
Clifton Medical Centre
Rotherham, S651DA, United Kingdom
Panthera Biopartners Limited - Sheffield
Sheffield, S2 5FX, United Kingdom
Bodyline Medical Clinic, St Helens Civia Health
St Helens, WA9 1AF, United Kingdom
FutureMeds Teesside
Stockton-on-Tees, TS19 8PE, United Kingdom
Bodyline Medical Clinic, Stoke-on-Trent Civia Health
Stoke-on-Trent, ST1 5TL, United Kingdom
Panthera Biopartners Limited - York
York, YO24 4LJ, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 29, 2025
First Posted
December 31, 2025
Study Start
December 19, 2025
Primary Completion (Estimated)
September 21, 2027
Study Completion (Estimated)
April 25, 2028
Last Updated
July 24, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.